Doseology Sciences (XCNQ:MOOD) Debt-to-EBITDA : 0.00 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Doseology Sciences Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Doseology Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.00 Mil. Doseology Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.00 Mil. Doseology Sciences's annualized EBITDA for the quarter that ended in Dec. 2023 was C$-0.44 Mil. Doseology Sciences's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Doseology Sciences's Debt-to-EBITDA or its related term are showing as below:

XCNQ:MOOD' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.47 Med: -0.43 Max: -0.03
Current: -0.03

During the past 4 years, the highest Debt-to-EBITDA Ratio of Doseology Sciences was -0.03. The lowest was -0.47. And the median was -0.43.

XCNQ:MOOD's Debt-to-EBITDA is ranked worse than
100% of 277 companies
in the Biotechnology industry
Industry Median: 1.36 vs XCNQ:MOOD: -0.03

Doseology Sciences Debt-to-EBITDA Historical Data

The historical data trend for Doseology Sciences's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Doseology Sciences Debt-to-EBITDA Chart

Doseology Sciences Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

Debt-to-EBITDA

-0.47

-0.43

-0.03

Doseology Sciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial										-0.52	-1.86	-0.01	-0.18	-

Competitive Comparison of Doseology Sciences's Debt-to-EBITDA

For the Biotechnology subindustry, Doseology Sciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Doseology Sciences's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Doseology Sciences's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Doseology Sciences's Debt-to-EBITDA falls into.

Doseology Sciences Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Doseology Sciences's Debt-to-EBITDA for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.043	+	0.008)	/	-1.679
	=	-0.03

Doseology Sciences's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	0)	/	-0.444
	=	0.00

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

Doseology Sciences (XCNQ:MOOD) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Doseology Sciences Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Doseology Sciences's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Doseology Sciences (XCNQ:MOOD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Doseology Sciences Inc (XCNQ:MOOD) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

DOSEF:USA

Address

116 - 5100 Anderson Way, Unit 197, Vernon, BC, CAN, V1T 0C4

Website

https://www.doseology.com

Doseology Sciences Inc is a diversified life sciences company, on a mission to reimagine mental health therapies through innovation, technology and sustainability. With a focus on the psychedelic and non-psychedelic compounds, also sale of its branded functional mushroom products. Doseology offers cutting-edge therapeutic products and services, with the aim of making a meaningful impact on the mental health pandemic and improving overall health.

Doseology Sciences (XCNQ:MOOD) Headlines

No Headlines